| Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma P Flamen, A Lerut, E Van Cutsem, W De Wever, M Peeters, S Stroobants, ... Journal of Clinical Oncology 18 (18), 3202-3210, 2000 | 729 | 2000 |
| Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal … A Hendlisz, MV Eynde, M Peeters, G Maleux, B Lambert, J Vannoote, ... Journal of clinical oncology 28 (23), 3687-3694, 2010 | 492 | 2010 |
| Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer P Flamen, E Van Cutsem, A Lerut, JP Cambier, K Haustermans, ... Annals of Oncology 13 (3), 361-368, 2002 | 415 | 2002 |
| Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR … G Gebhart, LE Lamberts, Z Wimana, C Garcia, P Emonts, L Ameye, ... Annals of oncology 27 (4), 619-624, 2016 | 343 | 2016 |
| Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with … T Lerut, P Flamen, N Ectors, E Van Cutsem, M Peeters, M Hiele, ... Annals of surgery 232 (6), 743-752, 2000 | 340 | 2000 |
| Bone health in cancer: ESMO clinical practice guidelines R Coleman, P Hadji, JJ Body, D Santini, E Chow, E Terpos, S Oudard, ... Annals of oncology 31 (12), 1650-1663, 2020 | 313 | 2020 |
| Additional Value of Whole-Body Positron Emission Tomography With Fluorine-18-2-Fluoro-2-deoxy-d-glucose in Recurrent Colorectal Cancer P Flamen, S Stroobants, E Van Cutsem, P Dupont, G Bormans, ... Journal of Clinical Oncology 17 (3), 894-894, 1999 | 306 | 1999 |
| Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value K Van Laere, S Ceyssens, F Van Calenbergh, T de Groot, J Menten, ... European journal of nuclear medicine and molecular imaging 32, 39-51, 2005 | 258 | 2005 |
| Whole-body PET with FDG for the diagnosis of recurrent gastric cancer T De Potter, P Flamen, E Van Cutsem, F Penninckx, L Filez, G Bormans, ... European journal of nuclear medicine and molecular imaging 29, 525-529, 2002 | 240 | 2002 |
| The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer P Flamen, A Lerut, E Van Cutsem, JP Cambier, A Maes, W De Wever, ... The Journal of Thoracic and Cardiovascular Surgery 120 (6), 1085-1092, 2000 | 232 | 2000 |
| Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET) P Flamen, OS Hoekstra, F Homans, E Van Cutsem, A Maes, S Stroobants, ... European journal of cancer 37 (7), 862-869, 2001 | 220 | 2001 |
| Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study S Rutkowski, S De Vleeschouwer, E Kaempgen, JEA Wolff, J Kühl, ... British journal of cancer 91 (9), 1656-1662, 2004 | 207 | 2004 |
| FDG-PET for preoperative staging of bladder cancer O Drieskens, R Oyen, H Van Poppel, Y Vankan, P Flamen, L Mortelmans European journal of nuclear medicine and molecular imaging 32, 1412-1417, 2005 | 198 | 2005 |
| Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres P Flamen, B Vanderlinden, P Delatte, G Ghanem, L Ameye, ... Physics in Medicine & Biology 53 (22), 6591, 2008 | 169 | 2008 |
| 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO G Gebhart, C Gámez, E Holmes, J Robles, C Garcia, M Cortés, ... Journal of Nuclear Medicine 54 (11), 1862-1868, 2013 | 167 | 2013 |
| Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? O Vrieze, K Haustermans, W De Wever, T Lerut, E Van Cutsem, N Ectors, ... Radiotherapy and oncology 73 (3), 269-275, 2004 | 166 | 2004 |
| Preservation of parotid function with uncomplicated conformal radiotherapy A Maes, C Weltens, P Flamen, P Lambin, R Bogaerts, X Liu, J Baetens, ... Radiotherapy and oncology 63 (2), 203-211, 2002 | 165 | 2002 |
| International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres H Levillain, O Bagni, CM Deroose, A Dieudonné, S Gnesin, OS Grosser, ... European journal of nuclear medicine and molecular imaging 48, 1570-1584, 2021 | 160 | 2021 |
| Evaluation of hypoxia in an experimental rat tumour model by [18F] fluoromisonidazole PET and immunohistochemistry L Dubois, W Landuyt, K Haustermans, P Dupont, G Bormans, ... British journal of cancer 91 (11), 1947-1954, 2004 | 137 | 2004 |
| Clinical impact of 68Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate … S Albisinni, C Artigas, F Aoun, I Biaou, J Grosman, T Gil, E Hawaux, ... BJU international 120 (2), 197-203, 2017 | 132 | 2017 |
